Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

Next Previous
Trial Profile

A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brigatinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ALTA
  • Sponsors ARIAD Pharmaceuticals; Takeda Pharma

    • Most Recent Events

    • 12 Sep 2023 Results comparing efficacy and safety of lorlatinib vs alectinib and brigatinib using matching adjusted indirect comparisons using patient level data from lorlatinib RCT (CROWN) to match the aggregate baseline characteristics of the comparator RCTs (alectinib: ALEX, ALESIA; brigatinib: ALTA-1L), presented at the 24th World Conference on Lung Cancer.
    • 08 Jun 2021 Final results of long-term efficacy and safety of the phase 1/2 and phase 2 trials (NCT01449461, NCT02094573) of BRG presented at the 57th Annual Meeting of the American Society of Clinical Oncology
    • 20 Aug 2020 Results (n=442) of population pharmacokinetics model based analysis from five clinical studies: ATLAS, AP26113-13-102, AP26113-13-103, AP26113-15-105 and NCT01449461published in the Clinical Pharmacokinetics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top